Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare total analgesic use at 24 hours after arthroscopic knee surgery in celecoxib-treated versus placebo-treated patients
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| B | Placebo Comparator |
| |
| A | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Other | Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total analgesic use (hydrocodone bitartrate 5 mg/acetaminophen 500 mg [HC/APAP]) after surgery | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Patient Assessment of Pain, according to visual analogue scale, after surgery at rest and flexion | 1, 2, 6, 8, 10, 12, 24, 36 hours | |
| Time to analgesic use after surgery | 1, 2, 6, 8, 10, 12, 24, 36 hours |
Not provided
Inclusion Criteria:
Inclusion criteria:
Exclusion Criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85023 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Celecoxib | Drug | 400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed |
|
| Number and percentage of patients taking HC/APAP after surgery | 1, 2, 6, 8, 10, 12, 24, 36 hours |
| Adverse events | Day 7 |
| Physical exam | Day 7 |
| Vital signs | Day 7 |
| Laboratory evaluation | Day 7 |
| St. Petersburg |
| Florida |
| 33713 |
| United States |
| Pfizer Investigational Site | Baltimore | Maryland | 21218 | United States |
| Pfizer Investigational Site | Timonium | Maryland | 21093 | United States |
| Pfizer Investigational Site | Springfield | Massachusetts | 01104 | United States |
| Pfizer Investigational Site | Springfield | Massachusetts | 01107 | United States |
| Pfizer Investigational Site | Springfield | Massachusetts | 01109 | United States |
| Pfizer Investigational Site | Springfield | Massachusetts | 01199 | United States |
| Pfizer Investigational Site | Springfield | Missouri | 65807 | United States |
| Pfizer Investigational Site | Columbia | South Carolina | 29202 | United States |
| Pfizer Investigational Site | Columbia | South Carolina | 29204 | United States |
| Pfizer Investigational Site | Columbia | South Carolina | 29212 | United States |
| Pfizer Investigational Site | Orangeburg | South Carolina | 29110 | United States |
| Pfizer Investigational Site | Johnson City | Tennessee | 37601 | United States |
| Pfizer Investigational Site | San Antonio | Texas | 78205 | United States |
| Pfizer Investigational Site | San Antonio | Texas | 78209 | United States |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | United States |
| Pfizer Investigational Site | San Antonio | Texas | 78240 | United States |
| ID | Term |
|---|---|
| D000068579 | Celecoxib |
| ID | Term |
|---|---|
| D000096926 | Benzenesulfonamides |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011720 | Pyrazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided